AZD-0284 is primarily investigated for its potential therapeutic applications in oncology, particularly for cancers associated with KRAS mutations, such as lung and pancreatic cancer. It functions as a kinase inhibitor targeting mutated KRAS proteins, which are commonly found in various cancers. By inhibiting these proteins, AZD-0284 disrupts signaling pathways that drive cancer cell growth and proliferation, helping to slow or halt tumor progression. This positions it as a promising candidate for treating KRAS-driven cancers. Ongoing research evaluates its efficacy, safety, and potential in combination with other therapies to improve outcomes and reduce resistance.